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Background and Research
Questions
Inflammatory processes are clearly im-
plicated in the aetiology of vascular disease
and in its sequelae [1]. Atherosclerosis
causes ischaemia and infarction by the
chronic or acute occlusion of arteries, and
inflammatory cells have been identified in
atherosclerotic lesions. Systemic markers of
inflammation such as interleukin-6 (IL-6),
C-reactive protein (CRP), fibrinogen, and
white cell count have previously been
shown to be associated with increased risk
of cardiovascular events in apparently
healthy populations and patients with
established vascular disease (e.g., [2,3]),
and in predicting the risk of, and outcome
after, stroke (reviewed in [4]). Although
inflammatory markers do improve predic-
tion of cardiovascular events, their predic-
tive value may be modest [5]. Others have
argued that the use of receiver operating
characteristic (ROC) curves and C-statistics
to decide the value of biomarkers may
underestimate their value in certain popu-
lations [6]. Recently, prediction of mortal-
ity was shown to be improved when
combinations of biomarkers are used [7].
Because healthy populations with CRP
over 2 mg/dl show reduced rates of fatal
and nonfatal cardiovascular events in
response to treatment with statin [8], it is
clinically important to clarify the role of
inflammatory markers in predicting out-
comes and the response to treatment.
Two Studies with Apparently
Conflicting Messages
Two studies published in PLoS Medi-
cine—one previously [9] and the other in
this issue [10]—that investigate the pre-
dictive value of inflammatory markers in
cardiovascular disease arrive at apparently
conflicting conclusions. Sattar et al. inves-
tigated over 5,000 men and women who
were aged 70–82 y and at high risk of
suffering cardiovascular events as part of
the PROSPER study [9]. In these indi-
viduals, who were randomised to placebo
or treatment with pravastatin, IL-6, CRP,
and fibrinogen all predicted cardiovascular
death, and IL-6 in particular added
significantly to conventional risk factors
in predicting those suffering fatal myocar-
dial infarction or fatal stroke. In contrast,
inflammatory markers were weak predic-
tors of nonfatal cardiovascular disease.
These conclusions were unaffected by
treatment with pravastatin. The implica-
tions are that the many studies pooling
fatal and nonfatal cardiovascular out-
comes may have inadvertently underesti-
mated the true predictive power of
inflammatory markers to predict fatal
AU cardiovascular events.
Elevated inflammatory markers also
predicted increased risk of noncardiovas-
cular death in this population, suggesting
these inflammatory markers are not nec-
essarily atherosclerosis-specific. Unrecog-
nised infection, chronic illness, and malig-
nancy, all potentially predisposing to
thrombosis, may play a role. The number
of patients actually reclassified from low to
high risk of fatal events as a result of
prespecified cutoff points of inflammatory
markers was not provided, and would help
assess the clinical value of adding inflam-
matory biomarkers to conventional risk
models. This is particularly important
given the age and baseline risk of the
population studied. The relevance of these
results to younger, lower-risk populations
will require further study.
Whiteley et al. investigated the potential
of inflammatory markers to add to the
prediction of functional outcomes in
patients suffering an acute stroke [10].
Using a simple six-variable prognostic
model as the reference, the researchers
performed a detailed evaluation of the
predictive value of inflammatory markers.
This evaluation included assessing the
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Linked Research Article
This Perspective discusses the fol-
lowing new study published in PLoS
Medicine:
Whiteley W, Jackson C, Lewis S,
Lowe G, Rumley A, et al. (2009)
Inflammatory Markers and Poor
Outcome after Stroke: A Prospec-
tive Cohort Study and Systematic
Review of Interleukin-6. PLoS Med
6(9): e1000145. doi:10.1371/journal.
pmed.1000145
In a prospective cohort study of
patient outcomes following stroke,
William Whiteley and colleagues
find that markers of inflammatory
response are associated with poor
outcomes. However, addition of
these markers to existing prognos-
tic models does not improve out-
come prediction.
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discrimination between subjects with good
or poor outcome, calibration to assess for
the relationship between predicted and
observed risk, and, most importantly,
reclassification of patient risk. By the
likelihood ratio statistic and by the ROC
curve, addition of IL-6 (or a composite of
IL-6, CRP, and white cell count) to the
six-variable model significantly improved
the prediction of outcomes. Similar quan-
titative relationships between IL-6 levels
and outcome were evident in the studies
included in their meta-analysis. However,
because only 5% of patients were reclas-
sified from an intermediate risk category to
a category with.90% or,10% risk of
poor outcome, the authors concluded that
the value of adding inflammatory markers
to prediction models was modest.
As the authors point out, only 60% of
patients had inflammatory markers mea-
sured, and this population experienced
milder strokes than the overall population,
raising concerns about the applicability of
the data to patients with more severe
strokes. A significant number of patients
had inflammatory markers drawn more
than 1 week after presentation (median 13
days), confusing elevated markers at base-
line with those emerging as a result of the
complications of stroke (such as urinary
tract infections). The number of patients
reclassified from indeterminate to deter-
minate risk categories is dependent upon
the percent risk used to define low (,10%)
or high (.90%) risk of poor outcome.
Although IL-6 may have improved reclas-
sification to a greater degree under less
stringent criteria to define low and high
risk (eg,20% and.80% respectively), the
clinical utility of these categories of risk is
uncertain.
Two Apparently Different
Conclusions
If the authors of the two studies have
reached different conclusions on the utility
of inflammatory markers, can, or should,
the results of the two studies be reconciled?
Sattar et al. used inflammatory markers to
predict cardiovascular mortality in a large
population without current infarctions,
whereas Whitely et al. used inflammatory
markers to predict functional outcomes in
patients presenting with stroke. In the
former, inflammatory markers provided
insights into inflammation as a predictor
or cause of life-threatening plaque rupture
and new arterial occlusions, or the survival
after such an event. In the latter, the
relationship of inflammatory markers to
the extent of neurological injury [11] and
to comorbidity, rather than propensity to
new arterial occlusions, was assessed. Thus
the pathologies in the two studies are quite
distinct. In addition, there are important
differences in the populations being stud-
ied and the questions being posed.
In large populations with a relatively
low incidence of disease, as in Sattar et al.,
a several-fold increase in risk can be
associated with a substantial increase in
the total number of events, and can
therefore permit reclassification of patients
from low to intermediate or high risk
categories, yet potentially not alter the
ROC curve C-statistics [6]. Where such
reclassification of calculated risk (e.g., 5
year risk of fatal myocardial infarction)
changes management by qualifying pa-
tients for primary prevention with medi-
cation such as aspirin or statins, a large
number of fatal cardiovascular events may
be prevented.
In the case of patients suffering from
stroke, prognostic stratification could be
used to determine optimal use of throm-
bolytic therapy or to decide on which
patients require treatment with statins or
other drugs. The denial of potentially life-
saving treatment in these patients requires
great confidence in the ability of the
biomarker (in conjunction with preexisting
risk predictors) to predict outcome. The
expectations of predictive models in these
circumstances are high in order to justify a
denial of treatment. The expectations are
harder still to meet when a relatively
simple and robust predictive model using
six clinical variables provides excellent
discrimination of outcomes as demonstrat-
ed by Whiteley et al.
Implications and Future
Directions
The study by Sattar et al. will prompt
reanalysis of the predictive value of IL-6,
CRP, and other inflammatory markers in
various patient populations. Clinicians
may need to consider cardiovascular
mortality, rather than total cardiovascular
events, when combining inflammatory
biomarkers with conventional Framing-
ham criteria to calculate absolute risk. The
study by Whiteley et al. will reassure
clinicians that clinically meaningful pre-
diction of outcomes after stroke is feasible
using a simple clinical score. Further
studies that include patients with more
severe strokes will be needed to resolve the
question of whether inflammatory markers
have predictive value in this population.
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